Licensing status

Publication and contact information


Alzheimer's disease (AD)

b-Amyloid (Ab); b-site APP-cleaving enzyme 1 (BACE1); mammalian target of rapamycin (mTOR; FRAP; RAFT1)

Mouse and cell culture studies suggest the plant-derived compound arctigenin could help treat AD. In a series of human cell lines, arctigenin decreased Ab production compared with vehicle by inhibiting BACE1 translation. In these cell lines, arctigenin inhibited mTOR signaling and also increased Ab clearance compared with vehicle. In a transgenic mouse model of AD, arctigenin decreased memory impairment and plaque formation in the brain compared with vehicle. Next steps include seeking an industry collaborator to help develop arctigenin to treat AD.

SciBX 6(34); doi:10.1038/scibx.2013.930
Published online Sept. 5, 2013

Patent pending covering arctigenin and its analogs; licensing status undisclosed

Zhu, Z. et al. J. Neurosci.;
published online Aug. 7, 2013;
Contact: Xu Shen, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Contact: Hualiang Jiang,
same affiliation as above
Contact: Lihong Hu, same affiliation as above